Bio-View Statistics

Total Valuation

Bio-View has a market cap or net worth of ILS 35.29 million. The enterprise value is 26.33 million.

Market Cap	35.29M
Enterprise Value	26.33M

Important Dates

The next estimated earnings date is Thursday, May 29, 2025.

Earnings Date	May 29, 2025
Ex-Dividend Date	n/a

Share Statistics

Bio-View has 131.67 million shares outstanding. The number of shares has decreased by -1.92% in one year.

Current Share Class	n/a
Shares Outstanding	131.67M
Shares Change (YoY)	-1.92%
Shares Change (QoQ)	-5.17%
Owned by Insiders (%)	51.60%
Owned by Institutions (%)	15.02%
Float	57.16M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.38
PB Ratio	1.54
P/TBV Ratio	1.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.36
EV / Sales	1.03
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.38

Financial Position

The company has a current ratio of 2.51, with a Debt / Equity ratio of 0.09.

Current Ratio	2.51
Quick Ratio	1.61
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.63
Interest Coverage	-13.83

Financial Efficiency

Return on equity (ROE) is -12.53% and return on invested capital (ROIC) is -6.67%.

Return on Equity (ROE)	-12.53%
Return on Assets (ROA)	-4.92%
Return on Invested Capital (ROIC)	-6.67%
Return on Capital Employed (ROCE)	-12.49%
Revenue Per Employee	777,424
Profits Per Employee	-95,394
Employee Count	33
Asset Turnover	0.68
Inventory Turnover	1.38

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.83% in the last 52 weeks. The beta is 0.39, so Bio-View's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	-4.83%
50-Day Moving Average	30.14
200-Day Moving Average	28.59
Relative Strength Index (RSI)	37.72
Average Volume (20 Days)	112,126

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Bio-View had revenue of ILS 25.66 million and -3.15 million in losses. Loss per share was -0.02.

Revenue	25.66M
Gross Profit	15.56M
Operating Income	-2.97M
Pretax Income	-2.86M
Net Income	-3.15M
EBITDA	-2.68M
EBIT	-2.97M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 10.94 million in cash and 1.98 million in debt, giving a net cash position of 8.96 million or 0.07 per share.

Cash & Cash Equivalents	10.94M
Total Debt	1.98M
Net Cash	8.96M
Net Cash Per Share	0.07
Equity (Book Value)	22.95M
Book Value Per Share	0.18
Working Capital	14.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -3.11 million and capital expenditures -35,000, giving a free cash flow of -3.14 million.

Operating Cash Flow	-3.11M
Capital Expenditures	-35,000
Free Cash Flow	-3.14M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross margin is 60.65%, with operating and profit margins of -11.59% and -12.27%.

Gross Margin	60.65%
Operating Margin	-11.59%
Pretax Margin	-11.14%
Profit Margin	-12.27%
EBITDA Margin	-10.43%
EBIT Margin	-11.59%
FCF Margin	n/a

Dividends & Yields

Bio-View does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.92%
Shareholder Yield	1.92%
Earnings Yield	-8.92%
FCF Yield	-8.90%

Stock Splits

The last stock split was on December 24, 2023. It was a forward split with a ratio of 10.

Last Split Date	Dec 24, 2023
Split Type	Forward
Split Ratio	10

Scores

Bio-View has an Altman Z-Score of 1.96. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.96
Piotroski F-Score	n/a